{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:57:04Z","timestamp":1787687824576,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ejphar.2014.01.006","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T18:02:41Z","timestamp":1389981761000},"page":"18-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy\u2014The PEARL randomized cross-over study"],"prefix":"10.1016","volume":"725","author":[{"given":"Francesco","family":"Pelliccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Marazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Spoletini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Franzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Speziale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Polacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.01.006_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jacc.2007.04.041","article-title":"Clopidogrel\u2013statin interaction: myth or reality?","volume":"50","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib2","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2010.11.024","article-title":"Clopidogrel-drug interactions","volume":"57","author":"Bates","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/hrt.2010.220509","article-title":"Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting","volume":"97","author":"Bouman","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.ejphar.2014.01.006_bib5","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.311.7013.1145","article-title":"Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons","volume":"311","author":"Campbell","year":"1995","journal-title":"B.M.J."},{"key":"10.1016\/j.ejphar.2014.01.006_bib7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","article-title":"Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship gene polymorphisms clinical outcomes","volume":"57","author":"Campo","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2014.01.006_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0037-1616220","article-title":"ADP receptors of platelets and their inhibition","volume":"86","author":"Gachet","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2014.01.006_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2013drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2014.01.006_bib11","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the, Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/mf.2006.28.5.990205","article-title":"Validation of VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel","volume":"28","author":"Malinin","year":"2006","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2796.2009.02119.x","article-title":"Influence of statin treatment on platelet inhibition by clopidogrel \u2013 a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment","volume":"266","author":"Malmstr\u00f6m","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejphar.2014.01.006_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.108.812636","article-title":"Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up","volume":"119","author":"Marcucci","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2014.01.006_bib16","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1093\/eurheartj\/ehs083","article-title":"Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study","volume":"33","author":"Park","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2014.01.006_bib17","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2008.06.038","volume":"52","author":"Patti","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.01.006_bib18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1160\/TH03-12-0738","article-title":"ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin","volume":"92","author":"Piorkowski","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejphar.2014.01.006_bib19","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","author":"Price","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2014.01.006_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1089\/gtmb.2011.0259","article-title":"Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing","volume":"16","author":"Saracini","year":"2012","journal-title":"Genet. Test. Mol. Biomark."},{"key":"10.1016\/j.ejphar.2014.01.006_bib21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ahj.2006.01.001","article-title":"Clopidogrel-statin interaction: a mountain or a mole hill?","volume":"152","author":"Steinhubl","year":"2006","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2014.01.006_bib22","first-page":"457","article-title":"The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease","volume":"266","author":"Vinholt","year":"2009","journal-title":"J. Intern. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T15:44:59Z","timestamp":1565106299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":21,"alternative-id":["S0014299914000077"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.006","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy\u2014The PEARL randomized cross-over study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}